Repligen Forms Scientific Advisory Board
WALTHAM, Mass., March 31, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced its formation of a Scientific Advisory Board (“SAB”) to provide thought leadership and oversight of the Company’s innovation initiatives. The SAB will focus on expansion of Repligen’s bioprocessing product portfolio as well as identification and evaluation of new strategic opportunities. It is comprised of some of the world’s most recognized experts and trailblazers in the field of biopharmaceutical manufacturing.
Charles L. Cooney, Robert T. Haslam Professor of Chemical Engineering, Emeritus, of the MIT Department of Chemical Engineering, and Faculty Director, Emeritus, of the Deshpande Center for Technological Innovation, has been named the Chairman of the SAB. “As a vocal proponent of stimulating technological innovation in bioprocessing, I am enthused to be leading the SAB at Repligen,” said Dr. Cooney.